La vendita allo scoperto per OncoCyte dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di OncoCyte. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

OncoCyte (NASDAQ:OCX) Azioni, Report sulle vendite allo scoperto

OncoCyte

OncoCyte Corporation Common Stock

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.

OncoCyte Corp

Piper Sandler analyst Scott Siefers maintains Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Underweight and raises the price target from $14 to $15.

News

Price Target

Analyst Ratings

HBAN

Piper Sandler Maintains Underweight on Huntington Bancshares, Raises Price Target to $15

Canaccord Genuity analyst George Gianarikas maintains ASP Isotopes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) with a Buy and maintains $4.5 price target.

ASPI

Canaccord Genuity Maintains Buy on ASP Isotopes, Maintains $4.5 Price Target

In the current market session, PNC Finl Servs Gr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) stock price is at $188.60, after a 0.11% decrease. However, over the past month, the company's stock spiked by 1.20%, and in the past year, by 71.91%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1729261810_0.png" alt="Past Year Chart" />

<h3>Evaluating PNC Finl Servs Gr P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 13.44 in the Banks industry, PNC Finl Servs Gr Inc. has a higher P/E ratio of 15.96. Shareholders might be inclined to think that PNC Finl Servs Gr Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729261810_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for PNC Finl Servs Gr

Canaccord Genuity analyst Kingsley Crane maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Hold and lowers the price target from $90 to $82.

OKTA

Canaccord Genuity Maintains Hold on Okta, Lowers Price Target to $82

Piper Sandler analyst Stephen Scouten maintains Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) with a Overweight and raises the price target from $30 to $31.

HOMB

Piper Sandler Maintains Overweight on Home BancShares, Raises Price Target to $31

Bernstein analyst Laurent Yoon maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Market Perform and raises the price target from $625 to $780.

NFLX

Bernstein Maintains Market Perform on Netflix, Raises Price Target to $780

Canaccord Genuity analyst Maria Ripps maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Hold and raises the price target from $750 to $760.

Canaccord Genuity Maintains Hold on Netflix, Raises Price Target to $760

Piper Sandler analyst Nathan Race maintains Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) with a Overweight and raises the price target from $22.5 to $23.

OSBC

Piper Sandler Maintains Overweight on Old Second Bancorp, Raises Price Target to $23

U.S. stocks traded mixed this morning, with the Dow Jones falling over 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.35% to 43,086.52 while the NASDAQ rose 0.73% to 18,507.31. The S&amp;P 500 also rose, gaining, 0.26% to 5,856.65.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Communication services shares jumped by 1.4% on Friday.
In trading on Friday, energy shares fell by 0.6%.
Top Headline
Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected third-quarter financial results, posting revenue of $9.825 billion, up 15% year-over-year, versus market estimates of $9.769 billion.
The company ended the third quarter with 282.72 million global paid subscribers, up 14.4% year-over-year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Catheter Precision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NASDAQ">VTAK</a>) shares shot up 249% to $1.54.</li>
<li>Shares of Bright Minds Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) got a boost, surging 133% to $50.66. The company announced a $35 million non-brokered private placement.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares were also up, gaining 96% to $15.55 after the company announced it filed a form RW and will not pursue a public offering at this time.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares dropped 38% to $0.4301.</li>
<li>Shares of Orgenesis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) were down 34% to $2.1100.</li>
<li>NuZee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) was down, falling 31% to $1.5950.</li>
</ul>
Commodities In commodity news, oil traded down 1.5% to $69.59 while gold traded up 0.8% at $2,730.00.
Silver traded up 2.9% to $32.690 on Friday, while copper rose 1.3% to $4.3815.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.1%, Germany's DAX rose 0.2% and France's CAC 40 climbed 0.2%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 fell 0.8%.
Construction output in the Eurozone fell by 2.5% year-over-year in August compared to a revised 2.3% decline in the previous month. The current account surplus in the Eurozone increased to €35.2 billion in August from €26.8 billion in the year-ago period.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index climbing 3.61%, China's Shanghai Composite Index gaining 2.91% and India's BSE Sensex gaining 0.27%.
Economics
<ul>
<li>U.S. housing starts fell by 0.5% from the previous month to an annualized rate of 1.354 million units in September.</li>
<li>Building permits declined by 2.9% to an annual rate of 1.428 million in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41402086/wall-streets-most-accurate-analysts-give-their-take-on-3-financials-stocks-delivering-hi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Trading Ideas

DRUG

NKGN

NUZE

ORGS

SOBR

VTAK

Dow Falls Over 100 Points; Netflix Posts Upbeat Results

Piper Sandler analyst Stephen Scouten maintains Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) with a Overweight and raises the price target from $58 to $63.

Piper Sandler Maintains Overweight on Bank OZK, Raises Price Target to $63

Canaccord Genuity analyst Brian McNamara maintains Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) with a Buy and maintains $13 price target.

HLMN

Canaccord Genuity Maintains Buy on Hillman Solns, Maintains $13 Price Target

Argus Research downgrades Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) from Buy to Hold.

Downgrades

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Argus Research Downgrades Elevance Health to Hold

Canaccord Genuity analyst Maria Ripps maintains Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Hold and raises the price target from $11 to $13.

Canaccord Genuity Maintains Hold on Viant Technology, Raises Price Target to $13

Autoliv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41398774/autoliv-financial-report-july-september-2024" rel="noreferrer noopener">trading higher on Friday.</a>
The company reported third-quarter adjusted earnings per share of $1.84, missing the analyst consensus of $1.95. Quarterly revenues of $2.56 billion topped the street view of $2.53 billion.
In the third quarter, sales fell by 0.8% organically. The firm performed well in Europe and Asia (excluding China) due to numerous product launches and favorable pricing.
Sales to domestic Chinese OEMs increased by 18%, outpacing their LVP growth of 8.5%. 
However, the firm struggled in China because of a negative mix, with sales of lower-safety models rising while higher-end models declined.
The company&#8217;s adjusted operating margin decreased to 9.3% from 9.4%.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/10/41399541/apple-iphone-16-sees-20-sales-surge-in-china-but-ai-absence-prompts-early-price-cuts" rel="noreferrer noopener">Apple iPhone 16 Sees 20% Sales Surge in China, But AI Absence Prompts Early Price Cuts</a>
&#8220;Light vehicle production was weak in the third quarter, declining by close to 5% globally. This was driven by a combination of inventory reductions, especially in the Americas and a high comparison base, especially in&nbsp;China,&#8221; said Mikael Bratt, President &amp; CEO.
The CEO indicated that, given recent sales trends and order intake, the company anticipates gaining more market share with domestic Chinese OEMs in the coming years.
Bratt also noted that negotiations for excess inflation compensation with customers have progressed as expected, although a few are still pending.
Outlook: Autoliv now expects full-year 2024 organic sales growth to be 1%, down from the previously anticipated 2%, <a href="https://www.benzinga.com/calendars/guidance">due to unfavorable market mix developments.</a>
With the seasonally strong fourth quarter remaining of the year, the company reaffirmed its guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
Price Action: ALV shares are trading higher by 5.69% to $99.24 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41388050/apples-3nm-push-boosts-taiwan-semis-q3-ai-revenue-set-to-triple-analyst" target="_blank" rel="noreferrer noopener">Apple&#8217;s 3nm Push Boosts Taiwan Semi&#8217;s Q3, AI Revenue Set To Triple: Analyst</a></li>
</ul>

Earnings

Guidance

Movers

General

Autoliv Surges Despite Mixed Q3 Results: Chinese Market Mix Drags  Performance

Piper Sandler analyst Adam Maeder reiterates Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and raises the price target from $495 to $538.

Reiteration

ISRG

Piper Sandler Reiterates Overweight on Intuitive Surgical, Raises Price Target to $538

Canaccord Genuity analyst Kingsley Crane maintains BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) with a Hold and raises the price target from $2.7 to $2.8.

Canaccord Genuity Maintains Hold on BlackBerry, Raises Price Target to $2.8

LYFT

Lyft Option Alert: 1,000 Contracts Of Oct 25 $14 Calls Swept Near The Ask At $0.26; Open Interest 2,062; Stock At $13.75 Ahead Of 11/6 Earnings

Piper Sandler analyst Matt O'Brien reiterates Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $200 to $225.

Piper Sandler Reiterates Overweight on Penumbra, Raises Price Target to $225

Alliance Global Partners initiates coverage on Global Self Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELF#NASDAQ">SELF</a>) with a Buy rating and announces Price Target of $6.5.

Initiation

SELF

Alliance Global Partners Initiates Coverage On Global Self Storage with Buy Rating, Announces Price Target of $6.5

At the <a href="https://www.benzinga.com/events/">Benzinga Cannabis Capital Conference</a>, actor and cannabis advocate Jim Belushi emphasized the urgent need for cannabis policy reform, particularly around banking and taxation. As the founder of Belushi's Farm, he's not only invested in the cultivation of cannabis, but also in changing the way the plant is regulated and perceived in both the medical and recreational spaces.
Belushi pointed out the stark contrast between how cannabis and alcohol are treated in terms of taxation, using Illinois as an example. "Last year, they collected $474 million in cannabis taxes and $272 million in liquor taxes. And there are a lot more liquor stores and bars than dispensaries," Belushi said, highlighting the disproportionate burden placed on the cannabis industry.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Benzinga&#39;s Abbey Higginbotham chatted with <a href="https://twitter.com/JimBelushi?ref_src=twsrc%5Etfw">@JimBelushi</a> – Founder, Belushi&#39;s Farm <a href="https://t.co/sdlOi13UvO">pic.twitter.com/sdlOi13UvO</a>
&mdash; Benzinga (@Benzinga) <a href="https://twitter.com/Benzinga/status/1844800130496553364?ref_src=twsrc%5Etfw">October 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Advocating For Change</h3>
Belushi has been a vocal proponent of cannabis reform, particularly the need to remove the plant from its classification as a Schedule I drug and to pass the Safe Banking Act, which would allow cannabis businesses more accessible access to financial services. "Let's get it off Schedule I. Let's pass the Banking Act. Let's bring down some regulations and over-taxation," he said.
He further stressed that cannabis offers a safer alternative to alcohol, saying, "Cannabis doesn't kill anybody. Alcohol does. It kills lots of people." This comparison underlines his argument for leveling the playing field between the two substances.
<h3 class="wp-block-heading">The Broader Impact of Cannabis Advocacy</h3>
Belushi also spoke about his broader advocacy for cannabis as a tool for healing, particularly in light of personal tragedies such as the loss of his brother John to an overdose. "Cannabis is a gentler alternative than opioids or overuse of alcohol to suppress anxiety and trauma," he said.
Through his platform and his involvement in the cannabis industry, Belushi is pushing for policy changes that not only benefit businesses but also help individuals find alternatives to harmful substances. As he noted, "People are suffering out there, and I think cannabis is the gentle way to help."
Belushi's continued efforts in the public and political arenas demonstrate his commitment to cannabis as more than just a business—it's a movement for broader social change.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Don't miss your chance to be part of Cannabis Market Spotlight: California in Anaheim on Nov. 12. Whether you want to connect with industry leaders, explore investment opportunities, or gain the latest insights into California's cannabis market, this event has it all.&nbsp;<a href="https://cannabismarketspotlight.com/california/anaheim-november-12/" target="_blank" rel="noreferrer noopener">Secure your spot today!</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free.&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe?_gl=1&#x2A;1ajl6va&#x2A;_gcl_au&#x2A;NjI5OTQ1MTM5LjE3Mjc5MzA5MjI.&#x2A;_ga&#x2A;MTAyOTE3MTY5OC4xNzI3OTMwOTIy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcyODkxMjAzOS41LjEuMTcyODkxMjEyMC4wLjAuMA.." target="_blank" rel="noreferrer noopener">Subscribe</a>&nbsp;to our newsletter here. You can't afford to miss out if you're serious about the business.
Jim Belushi speaks at the Benzinga Cannabis Capital Conference. Photo by Wendy Davis.

Cannabis

Politics

Events

Exclusives

Interview

EXCLUSIVE: Jim Belushi Speaks Out On Marijuana Reform, Says 'Cannabis Doesn't Kill Anybody, Alcohol Does'

OncoCyte GAAP EPS of -$0.36 beats by $0.19, revenue of $0.1M misses by $0.21M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
OncoCyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocx-stock-quote/">OCX</a>) just reported results for the second quarter of 2024.<ul><li>OncoCyte reported earnings per share of -36 cents. This was above the analyst estimate for EPS of -56 cents.</li><li>The company reported revenue of $104,000.</li><li>This was 67.50% worse than the analyst estimate for revenue of $320,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ocx-stock-earnings-oncocyte-for-q2-of-2024/">OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024

OncoCyte (OCX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham ...

OncoCyte's Growth Potential and Strategic Positioning Bolster Buy Rating

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

In a report released yesterday, Mark Massaro from BTIG reiterated a Hold rating on OncoCyte (OCX – Research Report). The company's shares closed ye...

BTIG Sticks to Their Hold Rating for OncoCyte (OCX)

Oncocyte gains 6% on $10.2M private placement

The latest update is out from OncoCyte ( ($OCX) ). Oncocyte Corporation has announced a private sale of over 3.4 million shares at $2.948 each to a...

OncoCyte Secures Funding Through Private Share Sale

In a report released today, Michael Matson from Needham reiterated a Buy rating on OncoCyte (OCX – Research Report), with a price target of $4.25. ...

OncoCyte's Strategic Shift and Market Potential Justify Buy Rating

An update from OncoCyte ( ($OCX) ) is now available. In a significant show of participation, holders of over 64% of voting shares attended a virtua...

Comments

OncoCyte

Vendite allo scoperto

OncoCyte (NASDAQ:OCX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO